Close Menu

NEW YORK (GenomeWeb) – Genomic Health reported today that its fourth quarter revenues rose 6 percent year over year, with sharper growth in international sales and prostate cancer testing than in the company's core US breast cancer market.

For the three months ended Dec. 31, 2017, Genomic Health's total revenues were $87.5 million compared to $82.7 million in the same period last year, missing the consensus Wall Street estimate of $88.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.